SecBot SecBot
SECBOTREPLAY Home › Report › ATRA

ATRA · Atara Biotherapeutics is holding its 2026 annual meeting to vote on…

Atara Biotherapeutics, Inc. · DEFA14A filed Apr 24, 2026 at 16:15 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Apr 24, 2026 at 16:15 ET

Atara Biotherapeutics is holding its 2026 annual meeting to vote on four key proposals: electing two directors, approving executive compensation, increasing shares in its equity incentive plan by 400,000, and ratifying Deloitte & Touche as its auditor. The filing is a routine proxy statement from management.

  • Annual meeting to vote on director elections, executive compensation, equity plan increase, and auditor ratification
  • Management is soliciting votes for all proposals
  • No activist involvement or contested board seats
  • Routine annual corporate governance matters

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access